NCT02653014View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

May 26, 2016

Study Completion Date

March 28, 2017

Conditions

HealthyRenal Insufficiency

Interventions

DRUG

KBP-5074

Trial Locations (1)

60805

Research by Design, LLC, Evergreen Park

Sponsors

Lead Sponsor

KBP Biosciences

All Listed Sponsors

lead

KBP Biosciences

INDUSTRY

NCT02653014 - Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment | Biotech Hunter | Biotech Hunter